257 related articles for article (PubMed ID: 18819799)
1. Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk).
Moriarty KJ; Takahashi H; Pullen SS; Khine HH; Sallati RH; Raymond EL; Woska JR; Jeanfavre DD; Roth GP; Winters MP; Qiao L; Ryan D; DesJarlais R; Robinson D; Wilson M; Bobko M; Cook BN; Lo HY; Nemoto PA; Kashem MA; Wolak JP; White A; Magolda RL; Tomczuk B
Bioorg Med Chem Lett; 2008 Oct; 18(20):5545-9. PubMed ID: 18819799
[TBL] [Abstract][Full Text] [Related]
2. Itk kinase inhibitors: initial efforts to improve the metabolical stability and the cell activity of the benzimidazole lead.
Moriarty KJ; Winters M; Qiao L; Ryan D; DesJarlis R; Robinson D; Cook BN; Kashem MA; Kaplita PV; Liu LH; Farrell TM; Khine HH; King J; Pullen SS; Roth GP; Magolda R; Takahashi H
Bioorg Med Chem Lett; 2008 Oct; 18(20):5537-40. PubMed ID: 18819794
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.
Cook BN; Bentzien J; White A; Nemoto PA; Wang J; Man CC; Soleymanzadeh F; Khine HH; Kashem MA; Kugler SZ; Wolak JP; Roth GP; De Lombaert S; Pullen SS; Takahashi H
Bioorg Med Chem Lett; 2009 Feb; 19(3):773-7. PubMed ID: 19111460
[TBL] [Abstract][Full Text] [Related]
4. 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).
Winters MP; Robinson DJ; Khine HH; Pullen SS; Woska JR; Raymond EL; Sellati R; Cywin CL; Snow RJ; Kashem MA; Wolak JP; King J; Kaplita PV; Liu LH; Farrell TM; DesJarlais R; Roth GP; Takahashi H; Moriarty KJ
Bioorg Med Chem Lett; 2008 Oct; 18(20):5541-4. PubMed ID: 18823779
[TBL] [Abstract][Full Text] [Related]
5. Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors.
Snow RJ; Abeywardane A; Campbell S; Lord J; Kashem MA; Khine HH; King J; Kowalski JA; Pullen SS; Roma T; Roth GP; Sarko CR; Wilson NS; Winters MP; Wolak JP; Cywin CL
Bioorg Med Chem Lett; 2007 Jul; 17(13):3660-5. PubMed ID: 17499505
[TBL] [Abstract][Full Text] [Related]
6. Indole RSK inhibitors. Part 1: discovery and initial SAR.
Boyer SJ; Burke J; Guo X; Kirrane TM; Snow RJ; Zhang Y; Sarko C; Soleymanzadeh L; Swinamer A; Westbrook J; Dicapua F; Padyana A; Cogan D; Gao A; Xiong Z; Madwed JB; Kashem M; Kugler S; O'Neill MM
Bioorg Med Chem Lett; 2012 Jan; 22(1):733-7. PubMed ID: 22100312
[TBL] [Abstract][Full Text] [Related]
7. Indole RSK inhibitors. Part 2: optimization of cell potency and kinase selectivity.
Kirrane TM; Boyer SJ; Burke J; Guo X; Snow RJ; Soleymanzadeh L; Swinamer A; Zhang Y; Madwed JB; Kashem M; Kugler S; O'Neill MM
Bioorg Med Chem Lett; 2012 Jan; 22(1):738-42. PubMed ID: 22056746
[TBL] [Abstract][Full Text] [Related]
8. Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors.
Kopecky DJ; Hao X; Chen Y; Fu J; Jiao X; Jaen JC; Cardozo MG; Liu J; Wang Z; Walker NP; Wesche H; Li S; Farrelly E; Xiao SH; Kayser F
Bioorg Med Chem Lett; 2008 Dec; 18(24):6352-6. PubMed ID: 18993068
[TBL] [Abstract][Full Text] [Related]
9. 5-Aminomethylbenzimidazoles as potent ITK antagonists.
Riether D; Zindell R; Kowalski JA; Cook BN; Bentzien J; Lombaert SD; Thomson D; Kugler SZ; Skow D; Martin LS; Raymond EL; Khine HH; O'Shea K; Woska JR; Jeanfavre D; Sellati R; Ralph KL; Ahlberg J; Labissiere G; Kashem MA; Pullen SS; Takahashi H
Bioorg Med Chem Lett; 2009 Mar; 19(6):1588-91. PubMed ID: 19246196
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK).
MacKinnon CH; Lau K; Burch JD; Chen Y; Dines J; Ding X; Eigenbrot C; Heifetz A; Jaochico A; Johnson A; Kraemer J; Kruger S; Krülle TM; Liimatta M; Ly J; Maghames R; Montalbetti CA; Ortwine DF; Pérez-Fuertes Y; Shia S; Stein DB; Trani G; Vaidya DG; Wang X; Bromidge SM; Wu LC; Pei Z
Bioorg Med Chem Lett; 2013 Dec; 23(23):6331-5. PubMed ID: 24138940
[TBL] [Abstract][Full Text] [Related]
11. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.
Zhang G; Ren P; Gray NS; Sim T; Liu Y; Wang X; Che J; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Chow D; Martin Seidel H; Karanewsky DS; He Y
Bioorg Med Chem Lett; 2008 Oct; 18(20):5618-21. PubMed ID: 18793846
[TBL] [Abstract][Full Text] [Related]
12. The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors.
Xiang Y; Hirth B; Asmussen G; Biemann HP; Bishop KA; Good A; Fitzgerald M; Gladysheva T; Jain A; Jancsics K; Liu J; Metz M; Papoulis A; Skerlj R; Stepp JD; Wei RR
Bioorg Med Chem Lett; 2011 May; 21(10):3050-6. PubMed ID: 21507633
[TBL] [Abstract][Full Text] [Related]
13. 2-Aminobenzimidazoles as potent ITK antagonists: trans-stilbene-like moieties targeting the kinase specificity pocket.
Lo HY; Bentzien J; Fleck RW; Pullen SS; Khine HH; Woska JR; Kugler SZ; Kashem MA; Takahashi H
Bioorg Med Chem Lett; 2008 Dec; 18(23):6218-21. PubMed ID: 18930400
[TBL] [Abstract][Full Text] [Related]
14. Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.
Sessions EH; Yin Y; Bannister TD; Weiser A; Griffin E; Pocas J; Cameron MD; Ruiz C; Lin L; Schürer SC; Schröter T; LoGrasso P; Feng Y
Bioorg Med Chem Lett; 2008 Dec; 18(24):6390-3. PubMed ID: 18996009
[TBL] [Abstract][Full Text] [Related]
15. Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors.
Orvieto F; Branca D; Giomini C; Jones P; Koch U; Ontoria JM; Palumbi MC; Rowley M; Toniatti C; Muraglia E
Bioorg Med Chem Lett; 2009 Aug; 19(15):4196-200. PubMed ID: 19541484
[TBL] [Abstract][Full Text] [Related]
16. 4-(1H-indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors.
Shafer CM; Lindvall M; Bellamacina C; Gesner TG; Yabannavar A; Jia W; Lin S; Walter A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4482-5. PubMed ID: 18672368
[TBL] [Abstract][Full Text] [Related]
17. Discovery and SAR of 2-amino-5-[(thiomethyl)aryl]thiazoles as potent and selective Itk inhibitors.
Das J; Liu C; Moquin RV; Lin J; Furch JA; Spergel SH; Doweyko AM; McIntyre KW; Shuster DJ; O'Day KD; Penhallow B; Hung CY; Kanner SB; Lin TA; Dodd JH; Barrish JC; Wityak J
Bioorg Med Chem Lett; 2006 May; 16(9):2411-5. PubMed ID: 16481166
[TBL] [Abstract][Full Text] [Related]
18. 'Reverse' alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Oct; 18(20):5456-9. PubMed ID: 18835164
[TBL] [Abstract][Full Text] [Related]
19. Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.
Anderson M; Andrews DM; Barker AJ; Brassington CA; Breed J; Byth KF; Culshaw JD; Finlay MR; Fisher E; McMiken HH; Green CP; Heaton DW; Nash IA; Newcombe NJ; Oakes SE; Pauptit RA; Roberts A; Stanway JJ; Thomas AP; Tucker JA; Walker M; Weir HM
Bioorg Med Chem Lett; 2008 Oct; 18(20):5487-92. PubMed ID: 18815031
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antitumor activity of novel benzimidazole-5-carboxylic acid derivatives and their transition metal complexes as topoisomerease II inhibitors.
Galal SA; Hegab KH; Hashem AM; Youssef NS
Eur J Med Chem; 2010 Dec; 45(12):5685-91. PubMed ID: 20884089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
